biostudies-literatureUnknown1Frank Peacock W<h4>Introduction</h4>Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is a rapidly acting (t½∼1 min) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efficacy of clevidipine in patients with RD.<h4>Methods</h4>VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 patients with persistent systolic blood pressure (SBP) >180 mmHg. Investigators pre-specified a SBP initial target range (ITR) for each patient to be achieved within 30 min. Blood pressure monitoring was by cuff. Clevidipine was infused via peripheral IV at 2 mg/h for at least 3 min, then doubled every 3 minBlood pressure. Supplement20-5https://www.ebi.ac.uk/biostudies/studies/S-EPMC3038587biostudies-literatureClevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.PMC3038587Pollack CVDunbar LVaron JEbrahimi RFrank Peacock WfalseClevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.<h4>Introduction</h4>Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is a rapidly acting (t½∼1 min) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efficacy of clevidipine in patients with RD.<h4>Methods</h4>VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 patients with persistent systolic blood pressure (SBP) >180 mmHg. Investigators pre-specified a SBP initial target range (ITR) for each patient to be achieved within 30 min. Blood pressure monitoring was by cuff. Clevidipine was infused via peripheral IV at 2 mg/h for at least 3 min, then doubled every 3 min2011-01-01T00:00:00Z2011 Apr2025-04-19T04:15:09.336Z2019-03-27T00:38:54ZS-EPMC30385872109126910.3109/08037051.2010.539317